Damora Therapeutics Stock (NASDAQ:DMRA)

Ownership Financials Chart

Previous Close

$20.27

52W Range

$3.50 - $38.33

50D Avg

$28.45

200D Avg

$26.36

Market Cap

$1.27B

Avg Vol (3M)

$543.76K

Beta

1.47

Div Yield

-

DMRA Company Profile

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

7

IPO Date

Oct 29, 2020

Website

DMRA Performance

DMRA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-210.87M	$-16.90M	$-36.46M
Net Income	$-209.84M	$-21.44M	$-38.35M
EBITDA	$-209.75M	$-21.22M	$-37.52M
Basic EPS	$-158.13	$-18.53	$-36.08
Diluted EPS	$-158.13	$-18.53	$-36.08

Fiscal year ends in Dec 25 | Currency in USD